Clinical Trial Update: Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating early treatment with an SGLT2 inhibitor in high-risk acute heart failure patients, and the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• SGLT2 inhibitor (class) (SGLT2 inhibitor)

Snippet

Sponsor: Juntendo University | Conditions: Acute Heart Failure | Phase 3 | Status: RECRUITING